Literature DB >> 18535890

New drugs for atrial fibrillation.

Matthias Hammwöhner1, Jan Smid, Uwe Lendeckel, Andreas Goette.   

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Epidemiologic studies suggest that the number of patients with AF will triple in the next 30 years, and therefore, its impact on medical and economic issues will further increase. Due to the limited efficacy and significant side effects of antiarrhythmic drugs, much effort has been made to develop alternative pharmacologic treatments for AF. Novel approaches include new antiarrhythmic drugs and novel drug targets involved in molecular, proarrhythmogenic, atrial remodeling. Furthermore, novel anticoagulants are now clinically studied. This review briefly summarizes new developments in the pharmacotherapy for AF.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18535890     DOI： 10.1007/s10840-008-9278-2

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN： 1383-875X            Impact factor:   1.900


  46 in total

1.  Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation.

Authors:  A Goette; P Hoffmanns; W Enayati; U Meltendorf; J C Geller; H U Klein
Journal:  Am J Cardiol       Date:  2001-10-15       Impact factor: 2.778

2.  Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.

Authors:  F Zannad; F Alla; B Dousset; A Perez; B Pitt
Journal:  Circulation       Date:  2000-11-28       Impact factor: 29.690

3.  Corticosteroids and the risk of atrial fibrillation.

Authors:  Cornelis S van der Hooft; Jan Heeringa; Guy G Brusselle; Albert Hofman; Jacqueline C M Witteman; J Herre Kingma; Miriam C J M Sturkenboom; Bruno H Ch Stricker
Journal:  Arch Intern Med       Date:  2006-05-08

4.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Authors:  D Li; S Fareh; T K Leung; S Nattel
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

Review 5.  Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery.

Authors:  Bengt I Eriksson; Daniel J Quinlan
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.

Authors:  Giuseppe Patti; Massimo Chello; Dario Candura; Vincenzo Pasceri; Andrea D'Ambrosio; Elvio Covino; Germano Di Sciascio
Journal:  Circulation       Date:  2006-09-25       Impact factor: 29.690

7.  Defective cardiac ryanodine receptor regulation during atrial fibrillation.

Authors:  John A Vest; Xander H T Wehrens; Steven R Reiken; Stephan E Lehnart; Dobromir Dobrev; Parag Chandra; Peter Danilo; Ursula Ravens; Michael R Rosen; Andrew R Marks
Journal:  Circulation       Date:  2005-04-26       Impact factor: 29.690

8.  ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs.

Authors:  Dezhi Xing; Anne Louise Kjølbye; Morten S Nielsen; Jørgen S Petersen; Kenneth W Harlow; Niels-Henrik Holstein-Rathlou; James B Martins
Journal:  J Cardiovasc Electrophysiol       Date:  2003-05

Review 9.  Nonchannel drug targets in atrial fibrillation.

Authors:  Andreas Goette; Uwe Lendeckel
Journal:  Pharmacol Ther       Date:  2004-04       Impact factor: 12.310

10.  Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model.

Authors:  Koichiro Kumagai; Hideko Nakashima; Naoki Gondo; Keijiro Saku
Journal:  J Cardiovasc Electrophysiol       Date:  2003-08
View more
  2 in total

1.  Biomarkers of structural remodelling and endothelial dysfunction for prediction of cardiovascular events or death in patients with atrial fibrillation.

Authors:  Joachim R Ehrlich; Magdalena Kaluzny; Stefan Baumann; Ralf Lehmann; Stefan H Hohnloser
Journal:  Clin Res Cardiol       Date:  2011-07-03       Impact factor: 5.460

Review 2.  Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes.

Authors:  Basil S Karam; Alejandro Chavez-Moreno; Wonjoon Koh; Joseph G Akar; Fadi G Akar
Journal:  Cardiovasc Diabetol       Date:  2017-09-29       Impact factor: 9.951
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.